Publicaciones en colaboración con investigadores/as de University Health Network (18)

2024

  1. Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results

    Alzheimer's and Dementia, Vol. 20, Núm. 5, pp. 3525-3542

  2. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Genetic Associations between Modifiable Risk Factors and Alzheimer Disease

    JAMA Network Open, Vol. 6, Núm. 5

  3. Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Núm. 36

2022

  1. Association of Rare APOE Missense Variants V236E and R251G with Risk of Alzheimer Disease

    JAMA Neurology, Vol. 79, Núm. 7, pp. 652-663

  2. Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort

    Cortex, Vol. 150, pp. 12-28

  3. Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

    Acta Neuropathologica, Vol. 144, Núm. 5, pp. 821-842

  4. Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia

    Neurobiology of Aging, Vol. 114, pp. 94-104

2021

  1. Differential early subcortical involvement in genetic FTD within the GENFI cohort

    NeuroImage: Clinical, Vol. 30

  2. Impairment of episodic memory in genetic frontotemporal dementia: A genfi study

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 13, Núm. 1

  3. Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients with Genetic Frontotemporal Dementia

    JAMA Network Open, Vol. 4, Núm. 1

2019

  1. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1)

    Nature Communications

  2. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2018

  1. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

    Nature Communications, Vol. 9, Núm. 1

  2. Germline variation at 8q24 and prostate cancer risk in men of European ancestry

    Nature Communications, Vol. 9, Núm. 1

2015

  1. Clinical correlations with lewy body pathology in LRRK2-related Parkinson disease

    JAMA Neurology, Vol. 72, Núm. 1, pp. 100-105

2010

  1. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP

    Neurobiology of Aging, Vol. 31, Núm. 5, pp. 725-731